A syringe and vial are seen in front of a displayed Pfizer logo in this illustration taken June 24, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

Pfizer Inc. on Nov. 2 said the company expected 2021 sales of the Covid-19 vaccine developed with German partner BioNTech SE would reach $36 billion and forecast another $29 billion from the shot in 2022, topping analyst estimates for both years.

Second-quarter 2021 sales of AstraZeneca’s Covid-19 vaccine more than tripled to $894 million from the first quarter, but the drugmaker on July 29 again delayed the U.S. application for approval as the company gathers more data for submissions.

Novartis reported second-quarter 2021 financials with net sales growing 15 percent to $12.96 billion. The company also reported on its Covid-19 vaccine production with CureVac and some pipeline updates.

One year after AbbVie’s $63 billion purchase of Allergan, the company is reportedly lining up the sale of a portfolio of women’s drugs and health care products valued at $5 billion.

Basel-based Lonza AG is moving to sell the company’s Lonza Specialty Ingredients division to private equity firms Bain Capital and Cinven for CHF 4.2 billion ($4.7 billion), completing a planned pivot to focus on Lonza Pharma, Biotech & Nutrition business. 

Gilead Sciences Inc. cut the company’s 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with Covid-19.

With more and more nations calling for self-quarantines due to the rapid spread of COVID-19 across the globe, companies are urging employees to work from home in order to decrease the spread of the virus.

Eli Lilly’s stock prices ticked up following the company’s announcement of strong quarterly sales and positive Phase III results in severe atopic dermatitis.

Novartis boss Vas Narasimhan expects higher sales and profitability for 2020, lifted by the company’s broad range of medicines, and minimal disruption to the Swiss drugmaker’s supply chain from the coronavirus outbreak in China.

Pfizer Inc. reported a higher-than-expected third-quarter 2019 profit on increased sales of the cancer drug Ibrance and a strong launch of the new heart medicine Vyndaqel.